Share on StockTwits

Jazz Pharmaceuticals plc - (NASDAQ:JAZZ) SVP Karen J. Wilson sold 2,500 shares of the stock in a transaction that occurred on Monday, July 7th. The stock was sold at an average price of $165.00, for a total transaction of $412,500.00. Following the completion of the sale, the senior vice president now directly owns 23,669 shares in the company, valued at approximately $3,905,385. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

A number of analysts have recently weighed in on JAZZ shares. Analysts at FBR Capital Markets reiterated a “top pick” rating on shares of Jazz Pharmaceuticals plc – in a research note on Wednesday, July 2nd. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Jazz Pharmaceuticals plc – in a research note on Friday, June 20th. They now have a $157.00 price target on the stock. Finally, analysts at JMP Securities initiated coverage on shares of Jazz Pharmaceuticals plc – in a research note on Tuesday, June 17th. They set an “outperform” rating and a $179.00 price target on the stock. Five analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Jazz Pharmaceuticals plc – presently has a consensus rating of “Buy” and a consensus target price of $168.60.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded down 0.12% during mid-day trading on Wednesday, hitting $154.70. 584,187 shares of the company’s stock traded hands. Jazz Pharmaceuticals plc – has a 52-week low of $70.33 and a 52-week high of $176.60. The stock has a 50-day moving average of $146.6 and a 200-day moving average of $144.2. The company has a market cap of $9.188 billion and a P/E ratio of 117.79.

Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last announced its earnings results on Thursday, May 8th. The company reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.79 by $0.18. The company had revenue of $247.00 million for the quarter, compared to the consensus estimate of $254.86 million. During the same quarter in the previous year, the company posted $1.37 earnings per share. The company’s revenue for the quarter was up 25.8% on a year-over-year basis. Analysts expect that Jazz Pharmaceuticals plc – will post $8.07 EPS for the current fiscal year.

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.